Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
Katey J. Rayner(University of Ottawa), Kathryn J. Moore(New York University), Allison L. McDaniel(Wake Forest University), Tathagat Dutta Ray(New York University), Janine M. van Gils(Leiden University Medical Center), Carlos Fernández‐Hernando(Yale University), Leigh Goedeke(Cardiovascular Institute of the South), Stephanie Marshall(Wake Forest University), Oleg G. Khatsenko(Regulus Therapeutics (United States)), Ryan E. Temel(University of Kentucky), Edward A. Fisher(Mount Sinai Hospital), Xueqing Liu(Duke-NUS Medical School), Vivek Kaimal(Regulus Therapeutics (United States)), Farah Hussain(New York University), Frederick J. Sheedy(Trinity College Dublin), Cynthia J. Lees(Wake Forest University), Christine Esau(Ionis Pharmaceuticals (United States))
Cited by 701
Related Papers
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
|Nature|2010|4k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k
CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer
|Nature Immunology|2009|1.5k